Related references
Note: Only part of the references are listed.How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
M. G. Brown et al.
NEUROLOGY (2007)
New natural history of interferon-β treated relapsing multiple sclerosis
Maria Trojano et al.
ANNALS OF NEUROLOGY (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
L. Kappos et al.
NEUROLOGY (2006)
The natural history of multiple sclerosis: a geographically based study - 9: Observations on the progressive phase of the disease
M Kremenchutzky et al.
BRAIN (2006)
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
CC Ford et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data
KP Johnson et al.
ACTA NEUROLOGICA SCANDINAVICA (2005)
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study
JK Lunceford et al.
STATISTICS IN MEDICINE (2004)
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis
S Vukusic et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2003)
Eight-year follow-up study of brain atrophy in patients with MS
E Fisher et al.
NEUROLOGY (2002)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
KP Johnson et al.
MULTIPLE SCLEROSIS JOURNAL (2000)
Share Paper
